SYLVESTRE G. QUEVEDO, M.D.; JEFFRY H. YOUNG, M.D.; BRIAN J. CARRIE, M.D.; HALSTED R. HOLMAN, M.D.
This content is PDF only. Please click on the PDF icon to access.
Continuous ambulatory peritoneal dialysis, the newest therapy for the treatment of renal failure, has been applied widely. A just-released study by the Office of Technology Assessment (OTA), The Effectiveness and Costs of Continuous Ambulatory Peritoneal Dialysis (CAPD) (1), is both more (in the issues raised) and less (in analytic conclusions) than its title implies. It is not an actual cost-effectiveness analysis of the new therapy compared with hemodialysis. "The data required to make the results of such an analysis meaningful simply do not exist," the report states. Bravo. Cost-effectiveness analysis is useful but does more harm than good when it
QUEVEDO SG, YOUNG JH, CARRIE BJ, et al. Continuous Ambulatory Peritoneal Dialysis: Bridging the Gap Between Evaluation and Practice in Chronic Illness. Ann Intern Med. 1986;104:430–432. doi: https://doi.org/10.7326/0003-4819-104-3-430
Download citation file:
Published: Ann Intern Med. 1986;104(3):430-432.
Nephrology, Renal Replacement Therapy.
Copyright © 2020 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use